Funded Tech Companies
VarmX
Headquartered in Leiden, VarmX has funding from BioGeneration Ventures, Libertatis Ergo Holding and InnovationQuarter Capital.
Company Overview
Company Name
VarmX
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Middelweg 38 B
Leiden, 2312 KJ
NL
Leiden, 2312 KJ
NL
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
VarmX is a spin-off from the Leiden University Medical Center (LUMC). The mission of VarmX is to develop and manufacture therapeutic proteins to restore hemostasis. VarmX's lead compound VMX-COO1 is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. Synthetic oral factor Xa inhibitors (such as edoxaban, rivaroxaban and apixaban) belong to the latest generation of anticoagulants and their world-wide use by patients at risk of thrombosis and stroke is increasing rapidly. However, usage of factor Xa inhibitors comes at the expense of a risk of uncontrolled and potentially life-threatening bleeding. To stop or prevent - the latter in the case of emergency surgery - these bleedings one needs a reversal agent as an antidote. VarmX has a product in its pipeline called VMX-COO1 that promises safe and effective reversal.
Last Transaction
5/25/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- BioGeneration Ventures
- Libertatis Ergo Holding
- InnovationQuarter Capital
- INKEF Capital
- European Innovation Council Fund
- Sound Bioventures
- EQT Life Sciences
- Lundbeckfonden BioCapital
- Ysios Capital
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs